DUBLIN, Aug. 6, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/dvlbwv/investigation) has announced the addition of the "Investigation Report on China's Recombinant Factor VIII Market, 2010-2019" report to their offering.
Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor VIII or IX, though not rare, which affects mostly males. Hemophilia A (clotting factor VIII deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor VIII while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor VIII (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor VIII too.
After entering China, recombinant factor VIII developed fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor VIII in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among of which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
As hemophiliacs' ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor VIII in China is expected to keep expanding.
Key Topics Covered:
1 Related Concepts of Recombinant Factor VIII
2 Market Profile of Recombinant Factor VIII in China
3 Survey on Sales Status of Recombinant Factor VIII in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Recombinant Factor VIII in China, 2010-2014
5 Survey on Dosage Forms of Recombinant Factor VIII in China, 2010-2014
6 Reference Price of Recombinant Factor VIII in Chinese Hospitals in 2014
7 Major Manufacturers of Recombinant Factor VIII in Chinese Market, 2010-2014
8 Market Outlook of Recombinant Factor VIII in China, 2015-2019
- Baxter Bioscience Manufacturing
- Wyeth Farma S.A.
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets